A Phase I, Single Centre, Double-Blind, Randomised, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability and Pharmacokinetics of Extended Release Tablets of AZD3241 After Administration of Multiple Ascending Doses in Healthy Male and Female Volunteers Including Food Effect.
Phase of Trial: Phase I
Latest Information Update: 01 Apr 2010
At a glance
- Drugs AZD 3241 (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- 01 Apr 2010 Actual patient number (77) added as reported by ClinicalTrials.gov.
- 01 Apr 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 10 Mar 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.